Synlogic

This Synthetic Biology Company Is On The Cusp Of Using Live, Engineered Bacteria As A Cancer Drug

Living medicines

Home » Health and medicine » Living medicines

Probiotics

Probiotics 2.0: Synthetic biology jumps into the human gut

Azitra

Poised for growth: how to scale a microbiome engineering company

Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure

BiomX Announces In-house Phage Manufacturing Facility

Azitra, Inc. Appoints Mark Sampson, Ph.D. as Chief Scientific Officer

Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia

Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development

Azitra Receives Ongoing Support for Its Netherton Development Program from the National Science Foundation (NSF)

Azitra Demonstrates Feasibility of Engineering the Skin Microbiome to Treat Serious Skin Conditions